 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., April 5, 2024 LEXINGTON, Mass...

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis to Present at Upcoming Healthcare Conferences in April Curis to Present at Upcoming Healthcare Conferences in April PR Newswire LEXINGTON, Mass., April 4, 2024 LEXINGTON, Mass., April 4, 2024...

Curis to Present at Upcoming Healthcare Conferences in April

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)

Q4 2023 Curis Inc Earnings Call Transcript

Curis (NASDAQ:CRIS  Get Free Report) and Ambrx Biopharma (NYSE:AMAM  Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two...

Financial Contrast: Curis (NASDAQ:CRIS) versus Ambrx Biopharma (NYSE:AMAM)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Curis price target lowered by $25 at H.C. Wainwright, here's why

Curis Provides Fourth Quarter 2023 Business Update Curis Provides Fourth Quarter 2023 Business Update PR Newswire LEXINGTON, Mass., Feb. 8, 2024 Emavusertib data presented at ASH showed 3 of 5...

Curis Provides Fourth Quarter 2023 Business Update

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024...

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., Jan. 5, 2024 LEXINGTON, Mass...

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Volume (M)	36,504.00
52-Wk High	$19.60
52-Wk Low	$3.80

CRIS Curis Inc

About

Feed

News

Sentiment

Earnings

Fundamentals